- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: PD-L1 positive
Total 16885 results
-
China Meitan General HospitalMarino Biotechnology Co., Ltd.UnknownRecurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant TumorsChina
-
Wuxi People's HospitalRecruitingCancer | PD-L1 Gene MutationChina
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Hoffmann-La RocheRecruitingPD-L1-selected Solid TumorsKorea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus, Georgia
-
Consorzio OncotechCompletedMetastatic or Locally Advanced PD-L1 Positive Urothelial CancerItaly
-
Zhongnan HospitalRecruiting
-
Medical University of ViennaUnknownNon Small Cell Lung CancerAustria
-
Baodong QinUnknown
-
Shanghai Zhongshan HospitalRecruiting
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Inge Marie SvaneCompletedPolycythemia Vera | Essential ThrombocythemiaDenmark
-
Tatarstan Cancer CenterUnknownHereditary Breast CancerRussian Federation
-
ImmunityBio, Inc.Active, not recruitingSolid Tumor | Metastatic Cancer | Locally Advanced Solid TumorUnited States
-
Lars Møller PedersenCompletedFollicular LymphomaDenmark
-
Hoffmann-La RocheCompletedCarcinoma, Non-Small-Cell Lung | Carcinoma, Small CellUnited Kingdom, Czechia, Germany, Poland, Spain, Switzerland
-
Centre Leon BerardNETRIS PharmaRecruitingAdvanced Solid Tumors | Metastatic Solid TumorsFrance
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
-
Sichuan UniversityNot yet recruitingAdvanced Solid TumorChina
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
Binhui Biopharmaceutical Co., Ltd.Recruiting
-
University Hospital, AngersCompletedCancer | Sleep Apnea Syndromes, ObstructiveFrance
-
Shanghai Zhongshan HospitalRecruitingCholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4China
-
Tongji HospitalNational Natural Science Foundation of ChinaRecruitingEsophageal Squamous Cell Carcinoma | Neoadjuvant TherapiesChina
-
Thomas MarronRecruiting
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdSunshine Lake Pharma Co., Ltd.Terminated
-
Peking Union Medical College HospitalRecruitingHepatocellular CarcinomaChina
-
Herlev and Gentofte HospitalUniversity of CopenhagenCompleted
-
Shanghai Zhongshan HospitalRecruitingOesophageal Squamous Cell CarcinomaChina
-
The Second Hospital of Nanjing Medical UniversityUnknownPrimary Hepatocellular Carcinoma
-
Merck Sharp & Dohme LLCActive, not recruitingBreast CancerJapan, Poland, United States, Australia, Belgium, Brazil, Canada, China, Colombia, Costa Rica, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Taiwan, Ukr... and more
-
Merck Sharp & Dohme LLCCompleted
-
Second Affiliated Hospital of Soochow UniversityNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
-
Sichuan UniversityRecruitingMalignant Ascites | Malignant Peritoneal Effusion | Serous Cavity MetastatisesChina
-
Sichuan UniversityRecruitingPleural Effusion, Malignant | Peritoneal Carcinoma MetastaticChina
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingNSCLC | Advanced Solid TumorUnited States, China
-
Lene Meldgaard KnudsenIO BiotechTerminatedSmoldering Multiple MyelomaDenmark
-
Fox Chase Cancer CenterGenentech, Inc.Active, not recruitingHER2-positive Breast CancerUnited States
-
Genentech, Inc.Completed
-
ImmunityBio, Inc.Active, not recruitingMelanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair DeficiencyUnited States
-
Lene Meldgaard KnudsenCompleted
-
Naestved HospitalRecruitingNon-small Cell Lung Cancer | Malignant Pleural EffusionDenmark
-
Shanghai Henlius BiotechRecruitingAdvanced Solid TumorChina
-
Ascletis Pharmaceuticals Co., Ltd.RecruitingHIV Infections | HIV-1-infection | PD-L1 Gene MutationChina
-
Kidney Cancer Research BureauRecruitingMetastatic Gastric Cancer | FGFR2 Amplification | PD-L1 Gene AmplificationUnited States
-
Merck Sharp & Dohme LLCActive, not recruitingCarcinoma, Non-squamous Non-small-cell LungPoland, Korea, Republic of, Ukraine, United States, Argentina, Australia, Austria, Canada, France, Japan, New Zealand, Romania, Russian Federation, Taiwan, Turkey, United Kingdom, Brazil, Colombia, Germany, Spain